MentionFox
Home › Executive changes › Aldeyra Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Aldeyra Therapeutics, Inc. executive changes

Every leadership change Aldeyra Therapeutics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Departures named1
Latest filing2026-06-10

Aldeyra Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-10. Between them they name 1 person. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-06-10 · 8-K

Reported

(d) On June 9, 2026, following Aldeyra Therapeutics, Inc.'s (the "Company") 2026 annual meeting of stockholders (the "2026 Annual Meeting"), and based upon the recommendation of the Nominating/Corporate Governance Committee of the Board of Directors (the "Board"), the Board appointed Darlene Deptula-Hicks as a Class III director, with her initial term expiring at the Company's 2029 annual meeting of stockholders.
Filed 2026-04-20 · 8-K

Departing: Martin J. Joyce, Director

(b) On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc. ("Aldeyra"), notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting").
Hiring for a seat like this?

Find people with the same kind of experience as the Director at Aldeyra Therapeutics, Inc., with the record behind each one.

Find candidates like Director at Aldeyra Therapeutics, Inc.
Selling to Aldeyra Therapeutics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Aldeyra Therapeutics, Inc. is in the news or changes leadership.

Get an alert when Aldeyra Therapeutics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Aldeyra Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/aldeyra-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Aldeyra Therapeutics, Inc. (ALDX) executive changes: 2 leadership filings. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/aldeyra-therapeutics